Massive Pharma is discovering it laborious to maintain up with challenges from biosimilar makers, together with Korean firms, quickly penetrating the worldwide market dominated by authentic medication, business watchers stated Friday.

Korean biosimilars are making strong challenges to original drugs in the global market.
Korean biosimilars are making robust challenges to authentic medication within the world market.

The rheumatoid arthritis remedy market is a living proof, the place originals’ gross sales have continued to drop within the face of biosimilars’ robust exhibiting.

The third-quarter sale of Janssen’s rheumatoid arthritis remedy Remicade (ingredient: infliximab) stood at $761 million, down 12.2 p.c from the identical interval final yr. This yr’s cumulative determine additionally remained at $2.42 billion, down 14.8 p.c from $2.84 billion a yr in the past. Within the U.S., the most important marketplace for infliximab therapies globally, Remicade posted gross sales of $2.58 billion, down 18.5 p.c.

Remicade’s income drop was on account of challenges from Korean biosimilars.

Celltrion and Samsung Bioepis are at present accelerating penetration within the U.S. Remicade market. Celltrion is working with Pfizer to promote Inflectra, and Samsung Bioepis sells Renflexis with Merck, referred to as MSD outdoors of the U.S. and Canada.

Inflectra’s market share within the U.S. was 10.7 p.c on the finish of final yr however soared to 22 p.c in October. It was the primary time a biosimilar had exceeded 20 p.c share within the Remicade market. Samsung Bioepis’ Renflexis additionally took a market share of seven p.c. In Europe, Inflectra has surpassed the unique product by taking 53 p.c of the market share.

In line with Pfizer, Inflectra recorded gross sales of $172 million within the first 9 months, up 6 p.c. Its cumulative gross sales additionally climbed 3 p.c to $485 million through the cited interval.

Pfizer’s rheumatoid arthritis remedy Enbrel (ingredient: etanercept) can be dropping its market share due to biosimilar merchandise.

Because the drug confronted competitors from biosimilars within the European market, gross sales fell 12 p.c within the third quarter of this yr to $283 million.

AbbVie has the identical considerations over biosimilars as its flagship product Humira (Ingredient: adalimumab), a rheumatoid arthritis remedy, is going through robust challenges from biosimilars.

Humira has accounted for about half of the corporate’s whole gross sales with $19.83 billion final yr. Within the first three quarters of this yr, it recorded $15.36, a 4.6 p.c enhance yr on yr.

The issue, nonetheless, is the U.S. market.

Humira’s patent expires in 2023 within the U.S. market, accounting for greater than 80 p.c of its world gross sales.

It stays to be seen whether or not Humira, the most important blockbuster drug within the world marketplace for years, will have the ability to repel the gross sales offensive by biosimilars after the patent’s expiry, in response to market watchers.

Humira performances in Europe again up such considerations. Its European gross sales plummeted in 2019 as a result of launch of a biosimilar following the expiry of patents. Final yr, Humira’s gross sales outdoors the U.S. dropped 12.5 p.c to $3.72 billion. Within the first 9 months of 2012, its worldwide gross sales besides America fell to $2.57 billion.

Humira’s rivals embrace Samsung Bioepis’ Imraldi, Amgen’s Amjevita, Sandoz’s Hyrimoz, and Mylan and Fujifilm Kyowa Kirin’s Hulio.

Amongst them, Samsung Imraldi’s development is steep. In line with its accomplice Biogen, Imraldi’s gross sales totaled $216.3 million final yr, up 17.6 p.c from 2019. The biosimilar additionally recorded $170.9 million in gross sales within the first 9 months of 2021, up 5.1 p.c.

AbbVie could even should brace up for worse conditions as a result of Humira’s sakes are anticipated to fall additional because the drug’s patent is about to run out within the U.S. in 2023, in response to the market sources.

Supply hyperlink

About Author

Leave a Reply

Leave a Reply

Your email address will not be published.

Translate »